normal human renal cortical epithelial cells hrce  (Lonza)

Journal: BMC Cancer

Article Title: Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion

doi: 10.1186/s12885-019-6096-0

Figure Lengend Snippet: Cell viability, cytotoxicity and cell cycle progression in TfRCC cell lines treated with mTOR inhibitors. a , b Cell viability, as measured by MTT assay for TfRCC cell lines and the benign renal epithelial cell line HRCE after 72 h of treatment with up to 1000 nM concentrations of the dual mTORC1/2 inhibitor, AZD8055 ( a ), or selective mTORC1 inhibitor, sirolimus ( b ). Viability in TfRCC cells was suppressed by approximately 80–90% with AZD8055 and 30–50% with sirolimus relative to the untreated (0 nM drug) condition. Both drugs inhibited growth to a greater degree in TfRCC cells than in benign renal cells. c , d Cell cytotoxicity, as measured by LDH release by UOK120 and UOK146 TfRCC cell lines after 48 h of treatment with 1 μM of AZD8055 ( c ) or sirolimus ( d ). Only slight cytotoxicity in UOK120 cells and no cytotoxicity in UOK146 cells was observed after AZD8055 treatment, while sirolimus treatment had no cytotoxic effect. Multi protein inhibitor LY294002 [100 μM] was used as a positive control. e , f Relative fraction of cells in S-phase of the cell cycle, as measured by BrdU incorporation in UOK120 ( e ) and UOK146 ( f ) cell lines treated for 24 h with low (50 nM) and high (500 nM) concentrations of AZD8055 or sirolimus. Dose-dependent reductions in S-phase in both cell lines with either drug mirror the magnitude of reductions observed in cell viability ( a , b ), supporting a predominantly cytostatic mechanism of growth inhibition for both drugs. * p < 0.05; ** p < 0.01; *** p < 0.001; NS = non-significant

Article Snippet: RCC4 was obtained from ECACC General Cell Collection (Salisbury, UK; Cat Nr. 03112702) and the human renal cortical epithelial (HRCE) cell line was obtained from ATCC (Manassas, VA; Cat Nr. PCS-400-011).

Techniques: MTT Assay, Positive Control, BrdU Incorporation Assay, Inhibition

Journal: Genes, chromosomes & cancer

Article Title: Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276)

doi: 10.1002/gcc.22476

Figure Lengend Snippet: Metabolic analysis of the UOK276 cell line. (A) Most chromophobe RCCs demonstrate increased expression of the genes encoding the components of the electron transport chain (ETC), while clear cell RCCs show decreased expression. TaqMan® mRNA expression analysis for a select number of ETC genes representing ETC complex I (NDUFA3, NDUFA6), ETC complex III (UQCRB), ETC complex IV (COX5A, COX6C), and ETC complex V (ATP5B) was performed to compare the UOK276 cell line with cell lines representing both normal human kidney (HRCE and RPTEC) and clear cell RCC (UOK139). Contrary to expectation, the UOK276 cell line demonstrated lower expression levels of the ETC genes than the normal human kidney cell lines and had an expression pattern that was more similar to the clear cell RCC cell line. (B) The oxygen consumption rate (OCR) for UOK276 was evaluated using a Seahorse XF96 Extracellular Flux Analyzer and compared with three normal kidney control cell lines (HK-2, PSC-400 and HRCE). The OCR was measured for 90 min and a comparison graph at the 60-min time point demonstrates a lower rate of oxygen consumption in the UOK276 cells that is consistent with the decreased expression of the ETC complex genes.

Article Snippet: The immortalized normal kidney cell line HK-2 and the normal human primary renal proximal tubule epithelial cells PSC-400 were purchased from the American Type Culture Collection (ATCC) and the normal human renal cortical epithelial cells HRCE were purchased from Lonza (Lonza Inc., NJ).

Techniques: Expressing, Control, Comparison